Scientists use ELISAs to assess the immunity and etiology of immune responses to coronavirus during the COVID-19 pandemic.

The World Health Organization–led program will promote equity in addition to facilitating access to samples, a WHO official involved in the project tells The Scientist.

New genomic analyses reveal that piscine orthoreovirus first came to the Pacific in 1989, around the same time that salmon farms in the area started importing Atlantic salmon eggs from Europe.

A letter signed by 18 researchers argues that hypotheses about zoonotic spillover or accidental lab release both “remain viable” in the absence of additional evidence.

By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.

Discover new RNA extraction and purification strategies and how they enable reliable and sensitive viral detection.

While some experts speculate the variant could be partially responsible for India’s current surge in SARS-CoV-2 infections, information about the effects of its mutations is only beginning to emerge.

An automated wastewater monitoring technique could enable researchers to predict outbreaks of the virus up to a week in advance.

Researchers use magnetic nanoparticles and liquid-handling robots in an effort to detect COVID-19 outbreaks early.

In a trio of studies, researchers follow up on a 40-year-old finding that certain bacteriophages replace adenine with so-called diaminopurine, perhaps to avoid host degradation.

Katie McKenna discusses a combination CAR T and viral therapy that kills solid tumors.

Researchers involved in a long-term project to identify viruses of concern have now assessed the risk factors that could help forecast which pathogens are the most likely to spillover from wildlife to people.

Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.

Researchers identify signatures that predict how a person will respond to an immune system stimulus.

Nicholas Hutchings will discuss how recombinant antibody technology can speed up the response to a pandemic.

Martha Nelson of the National Institute of Allergy and Infectious Diseases talks about the need to balance data sharing and patient privacy concerns when tracking the spread of variants.

Genetic analyses suggest that the virus came from a patient who survived the 2013–2016 West African outbreak.

Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.